Physician profile
Robert D Williams
NPI 1063596401
$1,750.54
in general payments reported to CMS, 2019-2025
16 companies · $22.74 in 2025
The $22.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $118 · 2021: $164 · 2023: $14.08 · 2024: $1,020 · 2025: $22.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $564 · Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $564.46 |
| Food and Beverage | $492.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $926.12 | 2019-2024 | |
| Eisai INC. | $245.80 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $166.75 | 2019-2021 | |
| Abbvie INC. | $83.63 | 2021-2025 | Vraylar |
| Livanova USA, INC. | $62.34 | 2019-2020 | |
| Pfizer INC. | $53.11 | 2024 | |
| Novartis Pharmaceuticals Corporation | $48.42 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.98 | 2019 | |
| Greenwich Biosciences, INC. | $24.45 | 2020-2021 | |
| Zogenix INC. | $22.55 | 2021 | |
| Ferring Pharmaceuticals INC. | $21.33 | 2024 | Adstiladrin |
| Strongbridge US INC. | $14.96 | 2019 | |
| Biomarin Pharmaceutical INC. | $14.46 | 2020 | |
| Cranial Technologies, INC | $14.22 | 2019 | |
| Merck Sharp & Dohme LLC | $13.22 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.